Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

被引：0

作者：

Chang, Darryl ^{[1
,2
]}

Habib, Alma ^{[2
,3
]}

Uegel, Andrew ^{[2
,4
]}

Struble, Emily ^{[2
,4
]}

Shaikh, Hira ^{[2
,4
]}

Strouse, Christopher ^{[2
,4
]}

Green, Kimberly M. ^{[2
,5
]}

Mushtaq, Muhammad Umair ^{[2
,6
]}

Mahmoudjafari, Zahra ^{[2
,6
]}

Hashmi, Hamza ^{[2
,7
]}

Mcguirk, Joseph P. ^{[2
,8
]}

Khan, Abdullah Mohammad ^{[2
,3
]}

Abdallah, Al-Ola ^{[2
,8
]}

Ahmed, Nausheen ^{[2
,6
]}

Atrash, Shebli ^{[1
,2
]}

Bhutani, Manisha ^{[1
,2
]}

机构：

[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[2] US Myeloma Innovat Res Collaborat USMIRC, Kansas City, KS USA

[3] Ohio State Univ, Div Hematol, Columbus, OH USA

[4] Univ Iowa Hosp & Clin, Div Hematol Oncol & Blood & Marrow Transplantat, Iowa, LA USA

[5] Med Univ South Carolina, Div Hematol Oncol, Charleston, SC USA

[6] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Westwood, KS USA

[7] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[8] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-208692

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2404 / 2405

页数：2

共 50 条

[21] Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Sidana, Surbhi
Patel, Krina K.
Peres, Lauren C.
Bansal, Radhika
Kocoglu, Mehmet H.
Shune, Leyla
Atrash, Shebli
Smith, Kinaya
Midha, Shonali
Ferreri, Christopher
Dhakal, Binod
Dima, Danai
Costello, Patrick
Wagner, Charlotte
Reshef, Ran
Hosoya, Hitomi
Mikkilineni, Lekha
Atanackovic, Djordje
Chhabra, Saurabh
Parrondo, Ricardo
Nadeem, Omar
Mann, Hashim
Kalariya, Nilesh
Hovanky, Vanna
De Avila, Gabriel
Freeman, Ciara L.
Locke, Frederick L.
Alsina, Melissa
Wong, Sandy
Herr, Megan
Htut, Myo
Mcguirk, Joseph
Sborov, Douglas W.
Khouri, Jack
Martin, Thomas
Janakiram, Murali
Lin, Yi
Hansen, Doris K.
BLOOD, 2025, 145 (01) : 85 - 97
[22] Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma
Berdeja, Jesus G.
Cohen, Adam D.
Martin, Thomas
Madduri, Deepu
Pacaud, Lida
Jagannath, Sundar
FUTURE ONCOLOGY, 2023, 19 (18) : 1235 - 1247
[23] Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison
Bar, Noffar
Diels, Joris
van Sanden, Suzy
Mendes, Joao
Hernando, Teresa
Burnett, Heather
Cost, Patricia
Schecter, Jordan M.
Lendvai, Nikoletta
Patel, Nitin
Ishida, Tadao
Er, Jeremy
Harrison, Simon J.
Lopez-Munoz, Nieves
CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (09) : 1597 - 1603
[24] Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
Delforge, Michel
Shah, Nina
Miguel, Jesus San F.
Braverman, Julia
Dhanda, Devender S.
Shi, Ling
Guo, Shien
Yu, Peiwen
Liao, Weiqin
Campbell, Timothy B.
Munshi, Nikhil C.
BLOOD ADVANCES, 2022, 6 (04) : 1309 - 1318
[25] Population pharmacokinetic modeling of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma.
Wu, Liviawati S.
Su, Yaming
Li, Claire
Zhou, Wangda
Jackson, Carolyn
Sun, Yu-Nien
Zhou, Honghui
CANCER RESEARCH, 2022, 82 (12)
[26] Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma
Hansen, Doris K.
Dhakal, Binod
Hamadani, Mehdi
Dingli, David
Jain, Tania
Huff, Carol Ann
Janakiram, Murali
Liu, Yi-Hsuan
De Braganca, Kevin C.
Lodowski, Nicole
Sander, Jennifer
Okorozo, Peter
Mcfarland, Lindsay
Perciavalle, Matthew
Huo, Stephen
Qureshi, Zaina P.
Patel, Krina K.
FRONTIERS IN IMMUNOLOGY, 2024, 15
[27] OUTCOMES OF IDECABTAGENE VICLEUCEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH BELANTAMAB MAFODOTIN
Melody, Megan
Przybylski, Daniel
Robinson, Adam
Lin, Adam
Gordon, Leo
Adekola, Kehinde
Singhal, Seema
Mehta, Jayesh
Moreira, Jonathan
BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 210 - 211
[28] Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma (vol 37, pg 1779, 2021)
Martin, Tom
Usmani, Saad Z.
Schecter, Jordan M.
Vogel, Martin
Jackson, Carolyn C.
Deraedt, William
Tian, Hong
Yeh, Tzu-min
Banerjee, Arnob
Pacaud, Lida
Garrett, Ashraf
Haltner, Anja
Cameron, Chris
Van Sanden, Suzy
Diels, Joris
Valluri, Satish
Samjoo, Imtiaz A.
CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (12) : 2197 - 2208
[29] Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
Mancuso, Katia
Barbato, Simona
Talarico, Marco
Tacchetti, Paola
Zamagni, Elena
Cavo, Michele
EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 27 - 46
[30] Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Bar, Noffar
Diels, Joris
van Sanden, Suzy
Mendes, Joao
Hernando, Teresa
Cost, Patricia
Schecter, Jordan M.
Lendvai, Nikoletta
Patel, Nitin
Ishida, Tadao
Jeremy, E. R.
Harrison, Simon J.
Lopez-Munoz, Nieves
BLOOD, 2023, 142

← 1 2 3 4 5 →